China Dongcheng Pharmaceutical Group – A Publicly Listed Integrated Pharmaceutical Enterprise

2026-01-15 19:48:38

China Dongcheng Pharmaceutical Group – A Publicly Listed Integrated Pharmaceutical Enterprise

China Dongcheng Pharmaceutical Group was founded in 1998 and successfully listed on the Shenzhen Stock Exchange in May 2012 (Stock Code: 002675). Over more than two decades of steady development, the Group has grown into a diversified pharmaceutical enterprise integrating research and development, large-scale manufacturing, and global commercialization.

Headquartered in Yantai, China, Yantai Dongcheng Pharmaceutical Group Co., Ltd. serves as the core operating entity of the Group’s biochemical API and pharmaceutical businesses.

Four Strategic Business Segments

Dongcheng has established a comprehensive industrial layout covering:

• Biochemical Active Pharmaceutical Ingredients (APIs)

• Chemical Medicines

• Proprietary Chinese Medicines

• Nuclide Drugs

This diversified structure strengthens risk management, enhances industrial synergy, and ensures sustainable long-term growth.

Global-Oriented Development Strategy

With a clear international vision, Dongcheng has built long-term partnerships with pharmaceutical companies across North America, Europe, Asia, the Middle East, and South America. Our global strategy focuses on:

• Regulatory compliance

• Technical innovation

• Stable production capacity

• Sustainable supply chain management

As a publicly listed pharmaceutical group, Dongcheng remains committed to high standards of corporate governance, transparency, and social responsibility.

Our mission is to provide safe, effective, and high-quality pharmaceutical raw materials that contribute to global healthcare development.